Implications of the Emerging SARS-CoV-2 Variant VUI 202012/01
Information about the Pfizer-BioNTech COVID-19 Vaccine
Communication Toolkit
New Variant of Virus that Causes COVID-19 Detected
Behavioural considerations for acceptance and uptake of COVID-19 vaccines
The Behavioural Insights Unit of the WHO released a meeting report of the Technical Advisory Group (TAG) on the special session on acceptance and uptake of COVID-19 vaccines, held on 15 October 2020. The meeting report outlines the factors that drive people’s behaviour in relation to vaccine acceptance and uptake: an enabling environment, social influences and motivation.
The image above is a visual narration that captures highlights of the meeting on 15 October 2020, during which the TAG on Behavioural Insights and Sciences for Health discussed behavioural considerations in relation to COVID-19 vaccine acceptance and uptake. The discussion was structured around three key questions. Click here to download image in full size.
Download the graphic
Joint statement calling for urgent country scale-up of access to optimal HIV treatment for infants and children living with HIV
First COVID-19 vaccine authorised for use in the European Union
On 21 December, EMA recommended granting a conditional marketing authorisation for the vaccine Comirnaty, developed by BioNTech and Pfizer, to prevent coronavirus disease 2019 (COVID-19) in people from 16 years of age. On the same day, the European Commission has granted market authorisation for EU-wide use.